COVID-19 in cancer patients: A retrospective study of 212 cases from a French SARS-CoV-2 cluster during the first wave of the COVID-19 pandemic.
Fiche publication
Date publication
mai 2021
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Pr KURTZ Jean-Emmanuel, Dr LIMACHER Jean-Marc, Dr GANTZER Justine, Dr PAMART Guillaume
Tous les auteurs :
Martin S, Kaeuffer C, Leyendecker P, Tuzin N, Tazi Y, Schaff-Wendling F, Kleinheny T, Husson-Wetzel S, Pamart G, Limacher JM, Clerc O, Dicop E, Kurtz JE, Barthélémy P, Gantzer J
Lien Pubmed
Résumé
We describe a large series of solid tumor patients in an early Coronavirus Disease 2019 (COVID-19) cluster of the eastern part of France. From February to May 2020, this multicenter retrospective study enrolled 212 cancer patients under treatment or on follow-up for any type of malignant solid tumor and positive for severe acute respiratory coronavirus 2. The mortality rate was 30%. Patients with gastrointestinal cancers were identified like a subset of more vulnerable cancer patients and immunotherapy or radiotherapy within 3 months from COVID-19 diagnosis were risk factors for death. The reported data support the essential need to be proactive and weigh the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies during this pandemic. IMPLICATIONS FOR PRACTICE: This article supports the essential need to be proactive (treatment delay or modification) in oncology in the setting of pandemic. Indeed, we identified gastrointestinal cancers like a subset of more vulnerable cancer patients and found that immunotherapy and radiotherapy within 3 months from COVID-19 diagnosis as risk factors for death. The reported data indicate the necessity to weigh the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies so that the situation would be different if there were another wave of COVID-19.
Mots clés
COVID-19, Cancer, mortality, patients' management, retrospective cohort, risk factor
Référence
Oncologist. 2021 May 24;: